Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Mylan Rejects Teva Buyout Offer
Teva seeks cushion against loss of patent protection | Financial Times
Mylan rejects Teva's $40.1 billion cash and stock offer
Mylan sues generic rival Teva over 'sophisticated scheme' to block Copaxone copycats | Fierce Pharma
Mylan/Viatris and Teva at the 38th Annual J.P. Morgan Healthcare Conference - MidgardFinance.com
Mylan/Viatris and Teva at the 38th Annual J.P. Morgan Healthcare Conference - MidgardFinance.com
Mylan Rejects Teva's $40 Billion Takeover Offer - The New York Times
Pfizer to spinoff, merge off-patent drugs unit with Mylan | Reuters
Teva offers to buy Mylan for $40.1 billion - The Economic Times
Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid | Reuters
Mylan says merger with Teva would be bad fit | Reuters
Teva may buy more Mylan stock despite antitrust allegations - Global Competition Review
Teva Makes $40.1 Billion Takeover Bid For Mylan | Mint
Israel's Teva drops bid for Mylan, buys Allergan for $40.5B | TribLIVE.com
Teva, Maker of Generic Drugs, Bids $40 Billion to Acquire Its Rival Mylan - The New York Times
Mylan-Pfizer off-patent merger boosts Teva - Globes
Teva bid for Mylan sparks worries of rising generic drug prices - The Economic Times
Mylan Raises Offer for Perrigo Again and Is Rejected Again - The New York Times
Look out, Teva: Mylan's Copaxone copy has already captured serious share | Fierce Pharma
Mylan rejects Teva's $40 billion merger offer as undervalued - The Economic Times
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Teva's Potential $40 bn Mylan acquisition could transform generics space'
Teva Offers to acquire Mylan for $40 billion in cash, stock | Pharma Companies
$40B deal: Teva offers to buy Mylan
